

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/79444 A2

(51) International Patent Classification⁷: C12N

(21) International Application Number: PCT/US01/12013

(22) International Filing Date: 12 April 2001 (12.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/229,358 12 April 2000 (12.04.2000) US
60/199,384 25 April 2000 (25.04.2000) US
60/256,931 21 December 2000 (21.12.2000) US

(71) Applicant (for all designated States except US): **HUMAN GENOME SCIENCES, INC** [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROSEN, Craig, A.** [US/US]; 22400 Rolling Hill Lane, Laytonsville, MD 20882 (US). **HASELTINE, William, A.** [US/US]; 3035 P. Street, N.W., Washington, DC 20007 (US).

(74) Agents: **WALE, Michele, M.** et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ALBUMIN FUSION PROTEINS

(57) Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.



WO 01/79444 A2

ALBUMIN FUSION PROTEINS

5

BACKGROUND OF THE INVENTION

The invention relates generally to Therapeutic proteins (including, but not limited to, a polypeptide, antibody, or peptide, or fragments and variants thereof) fused to albumin or fragments or variants of albumin. The invention further relates to Therapeutic proteins (including, but not limited to, a polypeptide, antibody, or peptide, or fragments and variants thereof) fused to albumin or fragments or variants of albumin, that exhibit extended shelf-life and/or extended or therapeutic activity in solution. These fusion proteins are herein collectively referred to as "albumin fusion proteins of the invention." The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells.

The invention is also directed to methods of *in vitro* stabilizing a Therapeutic protein via fusion or conjugation of the Therapeutic protein to albumin or fragments or variants of albumin.

Human serum albumin (HSA, or HA), a protein of 585 amino acids in its mature form (as shown in Figure 15 or in SEQ ID NO:18), is responsible for a significant proportion of the osmotic pressure of serum and also functions as a carrier of endogenous and exogenous ligands. At present, HA for clinical use is produced by extraction from human blood. The production of recombinant HA (rHA) in microorganisms has been disclosed in EP 330 451 and EP 361 991.

The role of albumin as a carrier molecule and its inert nature are desirable properties for use as a carrier and transporter of polypeptides *in vivo*. The use of albumin as a component of an albumin fusion protein as a carrier for various proteins has been suggested in WO 93/15199, WO 93/15200, and EP 413 622. The use of N-terminal fragments of HA for fusions to polypeptides has also been proposed (EP 399 666). Fusion of albumin to the Therapeutic protein may be achieved by genetic manipulation, such that the DNA coding for HA, or a fragment thereof, is joined to the DNA coding for the Therapeutic protein. A suitable host is then transformed or transfected with the fused nucleotide sequences, so

arranged on a suitable plasmid as to express a fusion polypeptide. The expression may be effected *in vitro* from, for example, prokaryotic or eukaryotic cells, or *in vivo* e.g. from a transgenic organism.

Therapeutic proteins in their native state or when recombinantly produced, such as
5 interferons and growth hormones, are typically labile molecules exhibiting short shelf-lives, particularly when formulated in aqueous solutions. The instability in these molecules when formulated for administration dictates that many of the molecules must be lyophilized and refrigerated at all times during storage, thereby rendering the molecules difficult to transport and/or store. Storage problems are particularly acute when pharmaceutical formulations must
10 be stored and dispensed outside of the hospital environment. Many protein and peptide drugs also require the addition of high concentrations of other protein such as albumin to reduce or prevent loss of protein due to binding to the container. This is a major concern with respect to proteins such as IFN. For this reason, many Therapeutic proteins are formulated in combination with large proportion of albumin carrier molecule (100-1000 fold excess),
15 though this is an undesirable and expensive feature of the formulation.

Few practical solutions to the storage problems of labile protein molecules have been proposed. Accordingly, there is a need for stabilized, long lasting formulations of proteinaceous therapeutic molecules that are easily dispensed, preferably with a simple formulation requiring minimal post-storage manipulation.

20

SUMMARY OF THE INVENTION

The present invention is based, in part, on the discovery that Therapeutic proteins may be stabilized to extend the shelf-life, and/or to retain the Therapeutic protein's activity for extended periods of time in solution, *in vitro* and/or *in vivo*, by genetically or chemically
25 fusing or conjugating the Therapeutic protein to albumin or a fragment (portion) or variant of albumin, that is sufficient to stabilize the protein and/or its activity. In addition it has been determined that the use of albumin-fusion proteins or albumin conjugated proteins may reduce the need to formulate protein solutions with large excesses of carrier proteins (such as albumin, unfused) to prevent loss of Therapeutic proteins due to factors such as binding to the
30 container.

The present invention encompasses albumin fusion proteins comprising a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) fused to albumin or a fragment (portion) or variant of albumin. The present invention also encompasses albumin fusion proteins comprising a Therapeutic protein (e.g., a polypeptide,
35 antibody, or peptide, or fragments and variants thereof) fused to albumin or a fragment (portion) or variant of albumin, that is sufficient to prolong the shelf life of the Therapeutic

protein, and/or stabilize the Therapeutic protein and/or its activity in solution (or in a pharmaceutical composition) *in vitro* and/or *in vivo*. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and
5 methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells.

The invention also encompasses pharmaceutical formulations comprising an albumin fusion protein of the invention and a pharmaceutically acceptable diluent or carrier. Such formulations may be in a kit or container. Such kit or container may be packaged with
10 instructions pertaining to the extended shelf life of the Therapeutic protein. Such formulations may be used in methods of treating, preventing, ameliorating, or diagnosing a disease or disease symptom in a patient, preferably a mammal, most preferably a human, comprising the step of administering the pharmaceutical formulation to the patient.

In other embodiments, the present invention encompasses methods of preventing
15 treating, or ameliorating a disease or disorder. In preferred embodiments, the present invention encompasses a method of treating a disease or disorder listed in the "Preferred Indication Y" column of Table 1 comprising administering to a patient in which such treatment, prevention or amelioration is desired an albumin fusion protein of the invention that comprises a Therapeutic protein portion corresponding to a Therapeutic protein (or fragment
20 or variant thereof) disclosed in the "Therapeutic Protein X" column of Table 1 (in the same row as the disease or disorder to be treated is listed in the "Preferred Indication Y" column of Table 1) in an amount effective to treat prevent or ameliorate the disease or disorder.

In another embodiment, the invention includes a method of extending the shelf life of a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants
25 thereof) comprising the step of fusing or conjugating the Therapeutic protein to albumin or a fragment (portion) or variant of albumin, that is sufficient to extend the shelf-life of the Therapeutic protein. In a preferred embodiment, the Therapeutic protein used according to this method is fused to the albumin, or the fragment or variant of albumin. In a most preferred embodiment, the Therapeutic protein used according to this method is fused to
30 albumin, or a fragment or variant of albumin, via recombinant DNA technology or genetic engineering.

In another embodiment, the invention includes a method of stabilizing a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) in solution, comprising the step of fusing or conjugating the Therapeutic protein to albumin or a
35 fragment (portion) or variant of albumin, that is sufficient to stabilize the Therapeutic protein. In a preferred embodiment, the Therapeutic protein used according to this method is fused to

the albumin, or the fragment or variant of albumin. In a most preferred embodiment, the Therapeutic protein used according to this method is fused to albumin, or a fragment or variant of albumin, via recombinant DNA technology or genetic engineering.

5 The present invention further includes transgenic organisms modified to contain the nucleic acid molecules of the invention, preferably modified to express the albumin fusion proteins encoded by the nucleic acid molecules.

BRIEF DESCRIPTION OF THE FIGURES

10 Figure 1 depicts the extended shelf-life of an HA fusion protein in terms of the biological activity (Nb2 cell proliferation) of HA-hGH remaining after incubation in cell culture media for up to 5 weeks at 37°C. Under these conditions, hGH has no observed activity by week 2.

15 Figure 2 depicts the extended shelf-life of an HA fusion protein in terms of the stable biological activity (Nb2 cell proliferation) of HA-hGH remaining after incubation in cell culture media for up to 3 weeks at 4, 37, or 50°C. Data is normalized to the biological activity of hGH at time zero.

20 Figures 3A and 3B compare the biological activity of HA-hGH with hGH in the Nb2 cell proliferation assay. Figure 3A shows proliferation after 24 hours of incubation with various concentrations of hGH or the albumin fusion protein, and Figure 3B shows proliferation after 48 hours of incubation with various concentrations of hGH or the albumin fusion protein.

25 Figure 4 shows a map of a plasmid (pPPC0005) that can be used as the base vector into which polynucleotides encoding the Therapeutic proteins (including polypeptide and fragments and variants thereof) may be cloned to form HA-fusions. Plasmid Map key: PRB1p: *PRB1 S. cerevisiae* promoter; FL: Fusion leader sequence; rHA: cDNA encoding HA; ADH1t: *ADH1 S. cerevisiae* terminator; T3: T3 sequencing primer site; T7: T7 sequencing primer site; Amp R: β -lactamase gene; ori: origin of replication. Please note that in the provisional applications to which this application claims priority, the plasmid in Figure 4 was labeled pPPC0006, instead of pPPC0005. In addition the drawing of this plasmid did not show certain pertinent restriction sites in this vector. Thus in the present application, the drawing is labeled pPPC0005 and more restriction sites of the same vector are shown.

30 Figure 5 compares the recovery of vial-stored HA-IFN solutions of various concentrations with a stock solution after 48 or 72 hours of storage.

35 Figure 6 compares the activity of an HA- α -IFN fusion protein after administration to monkeys via IV or SC.

Figure 7 describes the bioavailability and stability of an HA- α -IFN fusion protein.

Figure 8 is a map of an expression vector for the production of HA- α -IFN.

Figure 9 shows the location of loops in HA.

Figure 10 is an example of the modification of an HA loop.

5 Figure 11 is a representation of the HA loops.

Figure 12 shows the HA loop IV.

Figure 13 shows the tertiary structure of HA.

Figure 14 shows an example of a scFv-HA fusion

10 Figure 15 shows the amino acid sequence of the mature form of human albumin (SEQ ID NO:18) and a polynucleotide encoding it (SEQ ID NO:17).

DETAILED DESCRIPTION

As described above, the present invention is based, in part, on the discovery that a
Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants
15 thereof) may be stabilized to extend the shelf-life and/or retain the Therapeutic protein's
activity for extended periods of time in solution (or in a pharmaceutical composition) *in vitro*
and/or *in vivo*, by genetically fusing or chemically conjugating the Therapeutic protein,
polypeptide or peptide to all or a portion of albumin sufficient to stabilize the protein and its
activity.

20 The present invention relates generally to albumin fusion proteins and methods of
treating, preventing, or ameliorating diseases or disorders. As used herein, "albumin fusion
protein" refers to a protein formed by the fusion of at least one molecule of albumin (or a
fragment or variant thereof) to at least one molecule of a Therapeutic protein (or fragment or
variant thereof). An albumin fusion protein of the invention comprises at least a fragment or
25 variant of a Therapeutic protein and at least a fragment or variant of human serum albumin,
which are associated with one another, preferably by genetic fusion (i.e., the albumin fusion
protein is generated by translation of a nucleic acid in which a polynucleotide encoding all or a
portion of a Therapeutic protein is joined in-frame with a polynucleotide encoding all or a
portion of albumin) or chemical conjugation to one another. The Therapeutic protein and
30 albumin protein, once part of the albumin fusion protein, may be referred to as a "portion",
"region" or "moiety" of the albumin fusion protein (e.g., a "Therapeutic protein portion" or an
"albumin protein portion").

In one embodiment, the invention provides an albumin fusion protein comprising, or
alternatively consisting of, a Therapeutic protein (e.g., as described in Table 1) and a serum
35 albumin protein. In other embodiments, the invention provides an albumin fusion protein
comprising, or alternatively consisting of, a biologically active and/or therapeutically active

fragment of a Therapeutic protein and a serum albumin protein. In other embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a biologically active and/or therapeutically active variant of a Therapeutic protein and a serum albumin protein. In preferred embodiments, the serum albumin protein component of the albumin fusion protein is the mature portion of serum albumin.

In further embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein, and a biologically active and/or therapeutically active fragment of serum albumin. In further embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein and a biologically active and/or therapeutically active variant of serum albumin. In preferred embodiments, the Therapeutic protein portion of the albumin fusion protein is the mature portion of the Therapeutic protein. In a further preferred embodiment, the Therapeutic protein portion of the albumin fusion protein is the extracellular soluble domain of the Therapeutic protein. In an alternative embodiment, the Therapeutic protein portion of the albumin fusion protein is the active form of the Therapeutic protein.

In further embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a biologically active and/or therapeutically active fragment or variant of a Therapeutic protein and a biologically active and/or therapeutically active fragment or variant of serum albumin. In preferred embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, the mature portion of a Therapeutic protein and the mature portion of serum albumin.

Therapeutic proteins

As stated above, an albumin fusion protein of the invention comprises at least a fragment or variant of a Therapeutic protein and at least a fragment or variant of human serum albumin, which are associated with one another, preferably by genetic fusion or chemical conjugation.

As used herein, "Therapeutic protein" refers to proteins, polypeptides, antibodies, peptides or fragments or variants thereof, having one or more therapeutic and/or biological activities. Therapeutic proteins encompassed by the invention include but are not limited to, proteins, polypeptides, peptides, antibodies, and biologics. (The terms peptides, proteins, and polypeptides are used interchangeably herein.) It is specifically contemplated that the term "Therapeutic protein" encompasses antibodies and fragments and variants thereof. Thus an albumin fusion protein of the invention may contain at least a fragment or variant of a Therapeutic protein, and/or at least a fragment or variant of an antibody. Additionally, the term "Therapeutic protein" may refer to the endogenous or naturally occurring correlate of a

Therapeutic protein.

By a polypeptide displaying a "therapeutic activity" or a protein that is "therapeutically active" is meant a polypeptide that possesses one or more known biological and/or therapeutic activities associated with a Therapeutic protein such as one or more of the Therapeutic proteins described herein or otherwise known in the art. As a non-limiting example, a
5 "Therapeutic protein" is a protein that is useful to treat, prevent or ameliorate a disease, condition or disorder. As a non-limiting example, a "Therapeutic protein" may be one that binds specifically to a particular cell type (normal (e.g., lymphocytes) or abnormal e.g., (cancer cells)) and therefore may be used to target a compound (drug, or cytotoxic agent) to
10 that cell type specifically.

In another non-limiting example, a "Therapeutic protein" is a protein that has a biological activity, and in particular, a biological activity that is useful for treating preventing or ameliorating a disease. A non-inclusive list of biological activities that may be possessed by a Therapeutic protein includes, enhancing the immune response, promoting angiogenesis,
15 inhibiting angiogenesis, regulating hematopoietic functions, stimulating nerve growth, enhancing an immune response, inhibiting an immune response, or any one or more of the biological activities described in the "Biological Activities" section below.

As used herein, "therapeutic activity" or "activity" may refer to an activity whose effect is consistent with a desirable therapeutic outcome in humans, or to desired effects in
20 non-human mammals or in other species or organisms. Therapeutic activity may be measured *in vivo* or *in vitro*. For example, a desirable effect may be assayed in cell culture. As an example, when hGH is the Therapeutic protein, the effects of hGH on cell proliferation as described in Example 1 may be used as the endpoint for which therapeutic activity is measured. Such *in vitro* or cell culture assays are commonly available for many Therapeutic
25 proteins as described in the art. Examples of assays include, but are not limited to those described herein in the Examples section or in the "Exemplary Activity Assay" column of Table 1.

Therapeutic proteins corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention, such as cell surface and secretory proteins, are often modified
30 by the attachment of one or more oligosaccharide groups. The modification, referred to as glycosylation, can dramatically affect the physical properties of proteins and can be important in protein stability, secretion, and localization. Glycosylation occurs at specific locations along the polypeptide backbone. There are usually two major types of glycosylation: glycosylation characterized by O-linked oligosaccharides, which are attached to serine or
35 threonine residues; and glycosylation characterized by N-linked oligosaccharides, which are attached to asparagine residues in an Asn-X-Ser/Thr sequence, where X can be any amino

acid except proline. N-acetylneuramic acid (also known as sialic acid) is usually the terminal residue of both N-linked and O-linked oligosaccharides. Variables such as protein structure and cell type influence the number and nature of the carbohydrate units within the chains at different glycosylation sites. Glycosylation isomers are also common at the same site within a given cell type.

For example, several types of human interferon are glycosylated. Natural human interferon- $\alpha 2$ is O-glycosylated at threonine 106, and N-glycosylation occurs at asparagine 72 in interferon- $\alpha 14$ (Adolf *et al.*, J. Biochem 276:511 (1991); Nyman TA *et al.*, J. Biochem 329:295 (1998)). The oligosaccharides at asparagine 80 in natural interferon- $\beta 1\alpha$ may play an important factor in the solubility and stability of the protein, but may not be essential for its biological activity. This permits the production of an unglycosylated analog (interferon- $\beta 1b$) engineered with sequence modifications to enhance stability (Hosoi *et al.*, J. Interferon Res. 8:375 (1988; Karpusas *et al.*, Cell Mol Life Sci 54:1203 (1998); Knight, J. Interferon Res. 2:421 (1982); Runkel *et al.*, Pharm Res 15:641 (1998); Lin, Dev. Biol. Stand. 96:97 (1998))¹. Interferon- γ contains two N-linked oligosaccharide chains at positions 25 and 97, both important for the efficient formation of the bioactive recombinant protein, and having an influence on the pharmacokinetic properties of the protein (Sareneva *et al.*, Eur. J. Biochem 242:191 (1996); Sareneva *et al.*, Biochem J. 303:831 (1994); Sarèneva *et al.*, J. Interferon Res. 13:267 (1993)). Mixed O-linked and N-linked glycosylation also occurs, for example in human erythropoietin, N-linked glycosylation occurs at asparagine residues located at positions 24, 38 and 83 while O-linked glycosylation occurs at a serine residue located at position 126 (Lai *et al.*, J. Biol. Chem. 261:3116 (1986); Broudy *et al.*, Arch. Biochem. Biophys. 265:329 (1988)).

Therapeutic proteins corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention, as well as analogs and variants thereof, may be modified so that glycosylation at one or more sites is altered as a result of manipulation(s) of their nucleic acid sequence, by the host cell in which they are expressed, or due to other conditions of their expression. For example, glycosylation isomers may be produced by abolishing or introducing glycosylation sites, *e.g.*, by substitution or deletion of amino acid residues, such as substitution of glutamine for asparagine, or unglycosylated recombinant proteins may be produced by expressing the proteins in host cells that will not glycosylate them, *e.g.* in *E. coli* or glycosylation-deficient yeast. These approaches are described in more detail below and are known in the art.

Therapeutic proteins (particularly those disclosed in Table 1) and their nucleic acid sequences are well known in the art and available in public databases such as Chemical Abstracts Services Databases (e.g., the CAS Registry), GenBank, and GenSeq as shown in Table 1.

5 Additional Therapeutic proteins corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention include, but are not limited to, one or more of the Therapeutic proteins or peptides disclosed in the "Therapeutic Protein X" column of Table 1, or fragment or variable thereof.

10 Table 1 provides a non-exhaustive list of Therapeutic proteins that correspond to a Therapeutic protein portion of an albumin fusion protein of the invention. The "Therapeutic Protein X" column discloses Therapeutic protein molecules followed by parentheses containing scientific and brand names that comprise, or alternatively consist of, that Therapeutic protein molecule or a fragment or variant thereof. "Therapeutic protein X" as used herein may refer either to an individual Therapeutic protein molecule (as defined by the amino acid sequence obtainable from the CAS and Genbank accession numbers), or to the entire group of Therapeutic proteins associated with a given Therapeutic protein molecule disclosed in this column. The "Exemplary Identifier" column provides Chemical Abstracts Services (CAS) Registry Numbers (published by the American Chemical Society) and/or Genbank Accession Numbers ((e.g., Locus ID, NP_XXXXX (Reference Sequence Protein), and XP_XXXXX (Model Protein) identifiers available through the national Center for Biotechnology Information (NCBI) webpage at www.ncbi.nlm.nih.gov) that correspond to entries in the CAS Registry or Genbank database which contain an amino acid sequence of the Therapeutic Protein Molecule or of a fragment or variant of the Therapeutic Protein Molecule. In addition GenSeq Accession numbers and/or journal publication citations are given to identify the exemplary amino acid sequence for some polypeptides. The summary pages associated with each of these CAS and Genbank and GenSeq Accession Numbers as well as the cited journal publications (e.g., PubMed ID number (PMID)) are each incorporated by reference in their entirety, particularly with respect to the amino acid sequences described therein. The "PCT/Patent Reference" column provides U.S. Patent numbers, or PCT International Publication Numbers corresponding to patents and/or published patent applications that describe the Therapeutic protein molecule. Each of the patents and/or published patent applications cited in the "PCT/Patent Reference" column are herein incorporated by reference in their entirety. In particular, the amino acid sequences of the specified polypeptide set forth in the sequence listing of each cited "PCT/Patent Reference", the variants of these amino acid sequences (mutations, fragments, etc.) set forth, for example, in the detailed description of each cited "PCT/Patent Reference", the therapeutic indications set

forth, for example, in the detailed description of each cited "PCT/Patent Reference", and the activity assays for the specified polypeptide set forth in the detailed description, and more particularly, the examples of each cited "PCT/Patent Reference" are incorporated herein by reference. The "Biological activity" column describes Biological activities associated with the

5 Therapeutic protein molecule. The "Exemplary Activity Assay" column provides references that describe assays which may be used to test the therapeutic and/or biological activity of a Therapeutic protein or an albumin fusion protein of the invention comprising a Therapeutic protein X portion. Each of the references cited in the "Exemplary Activity Assay" column are herein incorporated by reference in their entireties, particularly with respect to the description

10 of the respective activity assay described in the reference (see Methods section, for example) for assaying the corresponding biological activity set forth in the "Biological Activity" column of Table 1. The "Preferred Indication Y" column describes disease, disorders, and/or conditions that may be treated, prevented, diagnosed, or ameliorated by Therapeutic protein X or an albumin fusion protein of the invention comprising a Therapeutic protein X portion.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
BMP-1	GeneSeq Accession P80618	WO8800205	BMP1 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic proteins induce cartilage and bone formation, play an important role in nephrogenesis, and play an important role in the development of many organs, including lung, heart, teeth, gut, skin, and particularly the kidney.	BMP-1 activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes
BMP-2	GeneSeq Accession P80619	WO8800205	BMP-2 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	BMP-2 activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes
BMP-2B	GeneSeq Accession W24850	US5631142	BMP-2b belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	BMP-2b activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes
BMP-4	GeneSeq Accession B02796	WO0020591	BMP-4 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	BMP-4 activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
BMP-5	GeneSeq Accession B02797	WO0020591	BMP-5 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	BMP-5 activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes
BMP-6	GeneSeq Accession R32904	US5187076	BMP-6 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	BMP-6 activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes
Osteogenic Protein-1; OP-1; BMP-7	GeneSeq Accession W34783	WO9734626	OP-1 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	OP-1 activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes
Osteogenic Protein-2	GeneSeq Accession R57973	WO9406399	OP-2 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	OP-2 activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
GDF-1	GeneSeq Accession R60961	WO9406449	Members of the TGF-beta family of proteins initiate cell signaling by binding to heteromeric receptor complexes of type I (TbetaRI) and type II (TbetaRII) serine/threonine kinase receptors (reviewed by Massague, J. et al. (1994) Trends Cell Biol. 4:172-178; Miyazono, K. et al. (1994) Adv. Immunol. 55:181-220). Activation of this heteromeric receptor complex occurs when TGF-beta. binds to TbetaRII, which then recruits and phosphorylates TbetaRI. Activated TbetaRI then propagates the signal to downstream targets (Chen, F. and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J. L. et al. (1994) Nature 370:341-347).	The effect of GDF-1 on signaling can be assayed by treating Primary BAECs transfected with a construct called p3TP-Lux, containing a TGF-beta responsive promoter fused to a reporter gene, and measuring luciferase gene expression (Wrana et al., 1994, Nature 370: 341-347).	Developmental disorders, Induction of Cartilage, Tissue and Bone Growth, and Diabetes
BMP-9	GeneSeq Accession R86903	WO9533830	BMP-9 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	BMP-9 activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
BMP-10	GeneSeq Accession R66202	WO9426893	BMP-10 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	BMP-10 activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes
BMP-12	GeneSeq Accession R78734	WO9516035	BMP-12 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	BMP-12 activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes
BMP-15	GeneSeq Accession W11261	WO9636710	BMP-15 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	BMP-15 activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes
BMP-17	GeneSeq Accession Y17870	WO9929718	BMP-17 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	BMP-17 activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
BMP-18	GeneSeq Accession Y17871	WO9929718	BMP-18 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	BMP-18 activity can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Induction of Cartilage, Tissue and Bone Growth, and Diabetes
Inhibin alpha	GeneSeq Accession B02806	WO0020591	The inhibin beta A subunit joins the alpha subunit to form a pituitary FSH secretion inhibitor. Inhibin has been shown to regulate gonadal stromal cell proliferation negatively and to have tumour-suppressor activity. In addition, serum levels of inhibin have been shown to reflect the size of granulosa-cell tumors and can therefore be used as a marker for primary as well as recurrent disease.	Tumor suppressor activity of inhibin can be determined using assays known in the art: Matzuk et al., Nature 1992 Nov 26;360(6402):313-9.	Tumor suppression.
Inhibin beta	GeneSeq Accession B02808	WO0020591	The inhibin beta A subunit joins the alpha subunit to form a pituitary FSH secretion inhibitor. Inhibin has been shown to regulate gonadal stromal cell proliferation negatively and to have tumour-suppressor activity. In addition, serum levels of inhibin have been shown to reflect the size of granulosa-cell tumors and can therefore be used as a marker for primary as well as recurrent disease.	Tumor suppressor activity of inhibin can be determined using assays known in the art: Matzuk et al., Nature 1992 Nov 26;360(6402):313-9.	Tumor suppression.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Cerebus Protein	GeneSeq Accession W86032	WO9849296	Cerebus is believed to be involved in the inhibition of BMP activity	BMP activity, in the presence of the antagonist Cerebus, can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	BMP Antagonist useful for Osteosarcoma, abnormal bone growth
Soluble BMP Receptor Kinase Protein-3	GeneSeq Accession R95227	WO9614579	Soluble BMP receptor kinase protein-3 is involved in the binding of BMPs. Soluble BMP receptor kinase protein-3 is useful as an antagonist for the inhibition of BMP activity	BMP activity, in the presence of the soluble antagonist BMP receptor kinase protein-3, can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	BMP Antagonist useful for Osteosarcoma, abnormal bone growth
BMP Processing Enzyme Furin	GeneSeq Accession W36099	WO9741250	BMPs belong to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation.	BMP activity, in the presence of the Furin, can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	Bone formation or Regeneration Abnormalities

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
TGF-beta 1	GeneSeq Accession R29657	WO9216228	Members of the TGF-beta family of proteins initiate cell signaling by binding to heteromeric receptor complexes of type I (TbtaRI) and type II (TbtaRII) serine/threonine kinase receptors (reviewed by Massague, J. et al. (1994) Trends Cell Biol. 4:172-178; Miyazono, K. et al. (1994) Adv. Immunol. 55:181-220). Activation of this heteromeric receptor complex occurs when TGF-beta. binds to TbtaRII, which then recruits and phosphorylates TbtaRI. Activated TbtaRI then propagates the signal to downstream targets (Chen, F. and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J. L. et al. (1994) Nature 370:341-347).	The effect of TGF betas on signaling can be assayed by treating Primary BAECs transfected with a construct called p3TP-Lux, containing a TGF-beta responsive promoter fused to a reporter gene, and measuring luciferase gene expression (Wrana et al., 1994, Nature 370: 341-347).	useful for treating cancer and to promote wound healing

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
TGF-beta 2	GeneSeq Accession R39659	EP542679	Members of the TGF-beta family of proteins initiate cell signaling by binding to heteromeric receptor complexes of type I (TbetaRI) and type II (TbetaRII) serine/threonine kinase receptors (reviewed by Massague, J. et al. (1994) Trends Cell Biol. 4:172-178; Miyazono, K. et al. (1994) Adv. Immunol. 55:181-220). Activation of this heteromeric receptor complex occurs when TGF-beta. binds to TbetaRII, which then recruits and phosphorylates TbetaRI. Activated TbetaRI then propagates the signal to downstream targets (Chen, F. and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J. L. et al. (1994) Nature 370:341-347).	The effect of TGF betas on signaling can be assayed by treating Primary BAECs transfected with a construct called p3TP-Lux, containing a TGF-beta responsive promoter fused to a reporter gene, and measuring luciferase gene expression (Wrana et al., 1994, Nature 370: 341-347).	useful for treating cancer and to promote wound healing

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
ZTGF-beta 9	GeneSeq Accession Y70654	WO0015798	Members of the TGF-beta family of proteins initiate cell signaling by binding to heteromeric receptor complexes of type I (TbetaRI) and type II (TbetaRII) serine/threonine kinase receptors (reviewed by Massague, J. et al. (1994) Trends Cell Biol. 4:172-178; Miyazono, K. et al. (1994) Adv. Immunol. 55:181-220). Activation of this heteromeric receptor complex occurs when TGF-beta: binds to TbetaRII, which then recruits and phosphorylates TbetaRI. Activated TbetaRI then propagates the signal to downstream targets (Chen, F. and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J. L. et al. (1994) Nature 370:341-347).	The effect of TGF betas on signaling can be assayed by treating Primary BAECs transfected with a construct called p3TP-Lux, containing a TGF-beta responsive promoter fused to a reporter gene, and measuring luciferase gene expression (Wrana et al., 1994, Nature 370: 341-347).	useful for treating cancer and to promote wound healing

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Anti-TGF beta family antibodies		GB2305921	Members of the TGF-beta family of proteins initiate cell signaling by binding to heteromeric receptor complexes of type I (TbetaRI) and type II (TbetaRII) serine/threonine kinase receptors (reviewed by Massague, J. et al. (1994) Trends Cell Biol. 4:172-178; Miyazono, K. et al. (1994) Adv. Immunol. 55:181-220). Activation of this heteromeric receptor complex occurs when TGF-beta. binds to TbetaRII, which then recruits and phosphorylates TbetaRI. Activated TbetaRI then propagates the signal to downstream targets (Chen, F. and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J. L. et al. (1994) Nature 370:341-347).	The effect of TGF betas on signaling, in the presence of an anti-TGF beta antibody, can be assayed by treating Primary BAEs transfected with a construct called p3TP-Lux, containing a TGF-beta responsive promoter fused to a reporter gene, and measuring luciferase gene expression (Wrana et al., 1994, Nature 370: 341-347).	Useful for control of fibrosis, immune, and inflammatory disease

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Latent TGF-beta binding protein II	GeneSeq Accession Y70552	WO0012551	Members of the TGF-beta family of proteins initiate cell signaling by binding to heteromeric receptor complexes of type I (TbetaRI) and type II (TbetaRII) serine/threonine kinase receptors (reviewed by Massague, J. et al. (1994) Trends Cell Biol. 4:172-178; Miyazono, K. et al. (1994) Adv. Immunol. 55:181-220). Activation of this heteromeric receptor complex occurs when TGF-beta. binds to TbetaRII, which then recruits and phosphorylates TbetaRI. Activated TbetaRI then propagates the signal to downstream targets (Chen, F. and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J. L. et al. (1994) Nature 370:341-347).	The effect of TGF betas on signaling, in the presence of a TGF-beta binding protein, can be assayed by treating Primary BAECs transfected with a construct called p3TP-Lux, containing a TGF-beta responsive promoter fused to a reporter gene, and measuring luciferase gene expression (Wrana et al., 1994, Nature 370: 341-347).	Useful for inhibiting tissue or tumor growth

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
MP52	GeneSeq Accession W36100	WO9741250	Members of the TGF-beta family of proteins initiate cell signaling by binding to heteromeric receptor complexes of type I (TbetaRI) and type II (TbetaRII) serine/threonine kinase receptors (reviewed by Massague, J. et al. (1994) Trends Cell Biol. 4:172-178; Miyazono, K. et al. (1994) Adv. Immunol. 55:181-220). Activation of this heteromeric receptor complex occurs when TGF-beta. binds to TbetaRII, which then recruits and phosphorylates TbetaRI. Activated TbetaRI then propagates the signal to downstream targets (Chen, F. and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J. L. et al. (1994) Nature 370:341-347).	The effect of TGF betas on signaling can be assayed by treating Primary BAECs transfected with a construct called p3TP-Lux, containing a TGF-beta responsive promoter fused to a reporter gene, and measuring luciferase gene expression (Wrana et al., 1994, Nature 370: 341-347).	Bone formation or Regeneration Abnormalities
b57 Protein	GeneSeq Accession W69293	WO9837195	BMPs are involved in the induction of bone formation. Specific antagonists are useful in preventing this activity from occurring.	BMP activity, in the presence of b57 protein, can be determined using the following assays known in the art: Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.	BMP Antagonist useful for Osteosarcoma, abnormal bone growth

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Resistin	GeneSeq Accession W69293	WO0064920	This gene belongs to the family defined by mouse FIZZ1 and FIZZ3/Resistin genes. The characteristic feature of this family is the C-terminal stretch of 10 cys residues with identical spacing. The mouse homolog of this protein is secreted by adipocytes, and may be the hormone potentially linking obesity to type II diabetes.	Ability of resistin to influence type II diabetes can be determined using assays known in the art: Pontoglio et al., J Clin Invest 1998 May 15;101(10):2215-22.	Type II diabetes and Syndrome X
Galectin-4	GeneSeq Accession W11841	WO9703190	Galectins are a family of carbohydrate-binding proteins characterized by an affinity for beta-galactoside containing glycoconjugates.	Ability of Galectin-4 polypeptides to bind lactose can be determined using assays known in the art: Wada et al., J Biol Chem 1997 Feb 28;272(9):6078-86.	Lactose intolerance
APM-1, ACRP-30; Famoxin	GeneSeq Accession Y71035	WO0026363	ACRP30 gene is exclusively expressed in adipose tissue. ACRP30 is thought to increase fatty acid oxidation by muscle tissue.	Ability of ACRP30 polypeptides to influence obesity and fat oxidation can be determined using assays known in the art: Fruebis et al., Proc Natl Acad Sci U S A 2001 Feb 13;98(4):2005-10.	Obesity, Metabolic disorders, Lipid Metabolism; Hormone Secretion
ACRP-30 Homologue; Complement Component C1q C	GeneSeq Accession B30234	WO0063376	ACRP30 gene is exclusively expressed in adipose tissue. ACRP30 is thought to increase fatty acid oxidation by muscle tissue.	Ability of ACRP30 homologue polypeptides to influence obesity and fat oxidation can be determined using assays known in the art: Fruebis et al., Proc Natl Acad Sci U S A 2001 Feb 13;98(4):2005-10.	Obesity, Metabolic disorders, Lipid Metabolism; Hormone Secretion
Calpain-10a	GeneSeq Accession Y79567	WO0023603	Calpain is believed to play a role in insulin secretion and insulin activity, and therefore may be useful in the treatment of type II diabetes.	Ability of Calpain-10 to influence type II diabetes can be determined using assays known in the art: Pontoglio et al., J Clin Invest 1998 May 15;101(10):2215-22.	Diabetes mellitus; Regulation of Insulin secretory response; Insulin mediated glucose transport disorders

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Calpain-10b	GeneSeq Accession Y79568	WO0023603	Calpain is believed to play a role in insulin secretion and insulin activity, and therefore may be useful in the treatment of type II diabetes.	Ability of Calpain-10 to influence type II diabetes can be determined using assays known in the art: Pontoglio et al., J Clin Invest 1998 May 15;101(10):2215-22.	Diabetes mellitus; Regulation of Insulin secretory response; Insulin mediated glucose transport disorders
Calpain-10c	GeneSeq Accession Y79569	WO0023603	Calpain is believed to play a role in insulin secretion and insulin activity, and therefore may be useful in the treatment of type II diabetes.	Ability of Calpain-10 to influence type II diabetes can be determined using assays known in the art: Pontoglio et al., J Clin Invest 1998 May 15;101(10):2215-22.	Diabetes mellitus; Regulation of Insulin secretory response; Insulin mediated glucose transport disorders
PDGF-D	GeneSeq Accession Y71130	WO0027879	Vascular Endothelial Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res 48: 4266)	Wound Healing; Atherosclerosis
FasL	GeneSeq Accession Y28594	WO9936079	Activities associated with apoptosis and immune system functions.	Activity can be determined using Apoptosis assays known in the art: Walczak et al. (1996) EMBOJ 16: 5386-5397.	Apoptosis-related disorders; Autoimmune disorders; Graft-v-Host disorders
Chondromodulin-like protein	GeneSeq Accession Y71262	WO0029579	Chondromodulin proteins are cartilage proteins thought to confer resistance to angiogenesis, and thus are useful as anti-angiogenic agents that may have utility in combating cancer.	Ability of Chondromodulin-like protein to inhibit vascularization can be determined using assays known in the art: Hiraki et al., J Biol Chem 1997 Dec 19;272(51):32419-26.	Antiangiogenic agent; Osteoblast proliferation stimulator; prevents vascularization of cartilage tissue; Useful to treat cancer.
Patched	GeneSeq Accession W72969	US5837538	Patched is a tumour-suppressor receptor for Sonic hedgehog (shh), which is a protein that controls developmental patterning and growth.	Ability of soluble Patched to bind to and inhibit the activities of shh can be determined using assays known in the art: Stone et al., Nature 1996 Nov 14;384(6605):129-34.	Receptor for Hedgehog cellular proliferation signaling molecule. This receptor is useful as a means of preventing cellular proliferation via the shh signaling pathway, thus useful for cancers.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Patched-2	GeneSeq Accession Y43261	WO9953058	Patched is a tumour-suppressor receptor for Sonic hedgehog (shh), which is a protein that controls developmental patterning and growth.	Ability of soluble Patched to bind to and inhibit the activities of shh can be determined using assays known in the art: Stone et al., Nature 1996 Nov 14;384(6605):129-34.	Receptor for Hedgehog cellular proliferation signaling molecule. This receptor is useful as a means of preventing cellular proliferation via the shh signaling pathway, thus useful for cancers.
Maspin; Protease Inhibitor 5	GeneSeq Accession R50938	WO9405804	Maspin is a member of the serpin family of serine protease inhibitors that is thought to suppress tumor metastasis.	The inhibitory effects of Maspin and other protease inhibitors can be assayed using methods known in the art such as a labeled protease substrate, for example, Universal Protease Substrate (casein, resorufin-labeled): Roche Molecular Biochemicals, Cat. No. 1080733.	Tumor suppressor which is down-regulated in breast cancers. The maspin protein has tumour suppressing and invasion suppressing activity
Endostatin	GeneSeq Accession B28399	WO0064946	Endostatin is believed to inhibit effects of capillary endothelial cell proliferation.	The inhibitory effects of endostatin can be assayed using assays disclosed by Cao et al (1996) J. Biol. Chem. 271 29461-29467	Anti-angiogenic activity. Useful in the prevention and/or treatment of cancers.
aFGF; FGF-1	GeneSeq Accession P94037	EP298723	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266); Examples 23 and 39 disclosed herein.	Promotion of growth and proliferation of cells, such as epithelial cells and keratinocytes. Antagonists may be useful as anti-cancer agents
bFGF; FGF2	GeneSeq Accession R06685	FR2642086	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266); Examples 23 and 39 disclosed herein.	Promotion of growth and proliferation of cells, such as epithelial cells and keratinocytes. Antagonists may be useful as anti-cancer agents

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
FGF-3; INT-2	GeneSeq Accession R07824	WO9503831	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266); Examples 23 and 39 disclosed herein.	Promotion of growth and proliferation of cells, such as epithelial cells and keratinocytes. Antagonists may be useful as anti-cancer agents
FGF-4; HST-1; HBGF-4	GeneSeq Accession R07825	WO9503831	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266); Examples 23 and 39 disclosed herein.	Promotion of growth and proliferation of cells, such as epithelial cells and keratinocytes. Antagonists may be useful as anti-cancer agents
FGF-5	GeneSeq Accession W22600	WO9730155	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266); Examples 23 and 39 disclosed herein.	Promotion of growth and proliferation of cells, such as epithelial cells and keratinocytes. Antagonists may be useful as anti-cancer agents
FGF-6; Heparin binding secreted transforming factor-2	GeneSeq Accession R58555	EP613946	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266); Examples 23 and 39 disclosed herein.	Promotion of growth and proliferation of cells, such as epithelial cells and keratinocytes. Antagonists may be useful as anti-cancer agents
FGF-8	GeneSeq Accession R80783	WO9524928	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266); Examples 23 and 39 disclosed herein.	Promotion of growth and proliferation of cells, such as epithelial cells and keratinocytes. Antagonists may be useful as anti-cancer agents

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
FGF-9; Glia activating factor	GeneSeq Accession R70822	WO9503831	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266); Examples 23 and 39 disclosed herein.	Promotion of growth and proliferation of cells, such as epithelial cells and keratinocytes. Antagonists may be useful as anti-cancer agents
FGF-12; Fibroblast growth factor homologous factor-1	GeneSeq Accession W06309	WO9635708	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266); Examples 23 and 39 disclosed herein.	Promotion of growth and proliferation of cells, such as epithelial cells and keratinocytes. Antagonists may be useful as anti-cancer agents
FGF-15	GeneSeq Accession Y08582	WO9927100	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266); Examples 23 and 39 disclosed herein.	Promotion of growth and proliferation of cells, such as epithelial cells and keratinocytes. Antagonists may be useful as anti-cancer agents
FGF-16	GeneSeq Accession Y05474	WO9918128	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266); Examples 23 and 39 disclosed herein.	Promotion of growth and proliferation of cells, such as epithelial cells and keratinocytes. Antagonists may be useful as anti-cancer agents
FGF-18	GeneSeq Accession Y08590	WO9927100	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266); Examples 23 and 39 disclosed herein.	Promotion of growth and proliferation of cells, such as epithelial cells and keratinocytes. Antagonists may be useful as anti-cancer agents

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
flt-3 ligand	GeneSeq Accession R67541	EP627487	Stem Cell Progenitor	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Promotion of immune cell growth and/or differentiation
VEGF-110	GeneSeq Accession Y69417	WO0013702	Promotes the growth and/or proliferation of endothelial cells	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
VEGF-121	GeneSeq Accession B50432	WO0071713	Promotes the growth and/or proliferation of endothelial cells	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
VEGF-138	GeneSeq Accession Y43483	WO9940197	Promotes the growth and/or proliferation of endothelial cells	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
VEGF-145	GeneSeq Accession Y69413	WO0013702	Promotes the growth and/or proliferation of endothelial cells	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
VEGF-162	GeneSeq Accession Y43484	WO9940197	Promotes the growth and/or proliferation of endothelial cells	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
VEGF-165	GeneSeq Accession Y69414	WO0013702	Promotes the growth and/or proliferation of endothelial cells	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
VEGF-182	GeneSeq Accession Y43483	WO9940197	Promotes the growth and/or proliferation of endothelial cells	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
VEGF-189	GeneSeq Accession Y69415	WO0013702	Promotes the growth and/or proliferation of endothelial cells	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
VEGF-206	GeneSeq Accession Y69416	WO0013702	Promotes the growth and/or proliferation of endothelial cells	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
VEGF-D	GeneSeq Accession W53240	WO9807832	Promotes the growth and/or proliferation of endothelial cells	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
VEGF-E; VEGF-X	GeneSeq Accession Y33679	WO9947677	Promotes the growth and/or proliferation of endothelial cells	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
VEGF Receptor; KDR; flk-1	GeneSeq Accession W69679	WO9831794	Receptor for VEGF polypeptides	VEGF activity, in the presence of flk-1 polypeptides, can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	VEGF Receptor. Fusion protein with the extracellular domain is useful as an anti-angiogenic agent. Agonists may be useful in the promotion of angiogenesis
Soluble VEGF Receptor	GeneSeq Accession W47037	US5712380	Receptor for VEGF polypeptides	VEGF activity, in the presence of VEGF Receptor polypeptides, can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	VEGF Receptor. Fusion protein with the extracellular domain is useful as an anti-angiogenic agent. Agonists may be useful in the promotion of angiogenesis
flt-1	GeneSeq Accession Y70751	WO0021560	Receptor for VEGF polypeptides	VEGF activity, in the presence of flt-1 polypeptides, can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	VEGF Receptor. Fusion protein with the extracellular domain is useful as an anti-angiogenic agent. Agonists may be useful in the promotion of angiogenesis

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
VEGF R-3; flt-4	GeneSeq Accession B29047	WO0058511	Receptor for VEGF polypeptides	VEGF activity, in the presence of flt-4 polypeptides, can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	VEGF Receptor. Fusion protein with the extracellular domain is useful as an anti-angiogenic agent. Agonists may be useful in the promotion of angiogenesis
Neuropilin-1	GeneSeq Accession Y06319	WO9929858	Vascular Endothelial Growth Factor	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
Neuropilin-2	GeneSeq Accession Y03618	WO9929858	Vascular Endothelial Growth Factor	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
Human fast twitch skeletal muscle troponin C	GeneSeq Accession W22597	WO9730085	Troponins are contractile proteins that are thought to inhibit angiogenesis. High levels may contribute to the difficulty encountered in revascularizing the ischemic myocardium after cardiovascular injury.	Ability of soluble Troponins to inhibit angiogenesis can be determined using assays known in the art. Proc Natl Acad Sci U S A 1999 Mar 16;96(6):2645-50.	Anti-angiogenesis
Human fast twitch skeletal muscle troponin I	GeneSeq Accession W22598	WO9730085	Troponins are contractile proteins that are thought to inhibit angiogenesis. High levels may contribute to the difficulty encountered in revascularizing the ischemic myocardium after cardiovascular injury.	Ability of soluble Troponins to inhibit angiogenesis can be determined using assays known in the art. Proc Natl Acad Sci U S A 1999 Mar 16;96(6):2645-50.	Anti-angiogenesis

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human fast twitch skeletal muscle troponin T	GeneSeq Accession W22599	WO9730085	Troponins are contractile proteins that are thought to inhibit angiogenesis. High levels may contribute to the difficulty encountered in revascularizing the ischemic myocardium after cardiovascular injury.	Ability of soluble Troponins to inhibit angiogenesis can be determined using assays known in the art.: Proc Natl Acad Sci U S A 1999 Mar 16;96(6):2645-50.	Anti-angiogenesis
fragment. myofibrillar protein Troponin I	GeneSeq Accession W18053	WO9719955	Troponins are contractile proteins that are thought to inhibit angiogenesis. High levels may contribute to the difficulty encountered in revascularizing the ischemic myocardium after cardiovascular injury.	Ability of soluble Troponins to inhibit angiogenesis can be determined using assays known in the art.: Proc Natl Acad Sci U S A 1999 Mar 16;96(6):2645-50.	Anti-angiogenesis
myofibrillar contractile protein Troponin I	GeneSeq Accession W18054	WO9719955	Troponins are contractile proteins that are thought to inhibit angiogenesis. High levels may contribute to the difficulty encountered in revascularizing the ischemic myocardium after cardiovascular injury.	Ability of soluble Troponins to inhibit angiogenesis can be determined using assays known in the art.: Proc Natl Acad Sci U S A 1999 Mar 16;96(6):2645-50.	Anti-angiogenesis
Troponin peptides	GeneSeq Accessions Y29581, Y29582, Y29583, Y29584, Y29585, and Y29586	WO9933874	Troponins are contractile proteins that are thought to inhibit angiogenesis. High levels may contribute to the difficulty encountered in revascularizing the ischemic myocardium after cardiovascular injury.	Ability of soluble Troponins to inhibit angiogenesis can be determined using assays known in the art.: Proc Natl Acad Sci U S A 1999 Mar 16;96(6):2645-50.	Anti-angiogenesis
Human fast twitch skeletal muscle Troponin subunit C.	GeneSeq Accession B00134	WO0054770	Troponins are contractile proteins that are thought to inhibit angiogenesis. High levels may contribute to the difficulty encountered in revascularizing the ischemic myocardium after cardiovascular injury.	Ability of soluble Troponins to inhibit angiogenesis can be determined using assays known in the art.: Proc Natl Acad Sci U S A 1999 Mar 16;96(6):2645-50.	Anti-angiogenesis

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human fast twitch skeletal muscle Troponin subunit I Protein	GeneSeq Accession B00135	WO0054770	Troponins are contractile proteins that are thought to inhibit angiogenesis. High levels may contribute to the difficulty encountered in revascularizing the ischemic myocardium after cardiovascular injury.	Ability of soluble Troponins to inhibit angiogenesis can be determined using assays known in the art.: Proc Natl Acad Sci U S A 1999 Mar 16;96(6):2645-50.	Anti-angiogenesis
Human fast twitch skeletal muscle Troponin subunit T	GeneSeq Accession B00136	WO0054770	Troponins are contractile proteins that are thought to inhibit angiogenesis. High levels may contribute to the difficulty encountered in revascularizing the ischemic myocardium after cardiovascular injury.	Ability of soluble Troponins to inhibit angiogenesis can be determined using assays known in the art.: Proc Natl Acad Sci U S A 1999 Mar 16;96(6):2645-50.	Anti-angiogenesis
Plasminogen Activator Inhibitor-1; PAI-1	GeneSeq Accession R08411	WO9013648	PAIs are believed to play a role in cancer, and cardiovascular disease and blood-clotting disorders.	Methods that measure plasminogen activator inhibitor (PAI) activity are known in the art, for example, assay the ability of PAI to inhibit tissue plasminogen activator (tPA) or urokinase (uPA): J Biochem Biophys Methods 2000 Sep 11;45(2):127-40, Breast Cancer Res Treat 1996;41(2):141-6. Methods that measure anti-angiogenesis activity are known in the art, for example, Proc Natl Acad Sci U S A 1999 Mar 16;96(6):2645-50.	Anti-angiogenesis; blood-clotting disorders.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Plasminogen Activator Inhibitor-2; PAI-2	GeneSeq Accession P94160	DE3722673	PAIs are believed to play a role in cancer, and cardiovascular disease and blood-clotting disorders.	Methods that measure plasminogen activator inhibitor (PAI) activity are known in the art, for example, assay the ability of PAI to inhibit tissue plasminogen activator (tPA) or urokinase (uPA): J Biochem Biophys Methods 2000 Sep 11;45(2):127-40, Breast Cancer Res Treat 1996;41(2):141-6. Methods that measure anti-angiogenesis activity are known in the art, for example, Proc Natl Acad Sci U S A 1999 Mar 16;96(6):2645-50.	Anti-angiogenesis; blood-clotting disorders.
Plasminogen Activator Inhibitor-2; PAI-2	GeneSeq Accession R10921	WO9102057	PAIs are believed to play a role in cancer, and cardiovascular disease and blood-clotting disorders.	Methods that measure plasminogen activator inhibitor (PAI) activity are known in the art, for example, assay the ability of PAI to inhibit tissue plasminogen activator (tPA) or urokinase (uPA): J Biochem Biophys Methods 2000 Sep 11;45(2):127-40, Breast Cancer Res Treat 1996;41(2):141-6. Methods that measure anti-angiogenesis activity are known in the art, for example, Proc Natl Acad Sci U S A 1999 Mar 16;96(6):2645-50.	Anti-angiogenesis; blood-clotting disorders.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human PAI-1 mutants	GeneSeq Accessions R11755, R11756, R11757, R11758, R11759, R11760, R11761, R11762, and R11763	WO9105048	PAIs are believed to play a role in cancer, and cardiovascular disease and blood-clotting disorders.	Methods that measure plasminogen activator inhibitor (PAI) activity are known in the art, for example, assay the ability of PAI to inhibit tissue plasminogen activator (tPA) or urokinase (uPA): J Biochem Biophys Methods 2000 Sep 11;45(2):127-40, Breast Cancer Res Treat 1996;41(2):141-6. Methods that measure anti-angiogenesis activity are known in the art, for example, Proc Natl Acad Sci U S A 1999 Mar 16;96(6):2645-50.	Anti-angiogenesis; blood-clotting disorders.
CXCR3; CXCR3 chemokine receptor 3	GeneSeq Accession Y79372	WO0018431	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Soluble CXCR3 polypeptides may be useful for inhibiting chemokine activities and viral infection.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Modified Rantes	GeneSeq Accession W38129	WO9737005	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Immune disorders

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
RANTES	GeneSeq Accession Y05299	EP905240	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Immune disorders

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
MCP-1a	GeneSeq Accession R73914	WO9509232	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Immune disorders

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
MCP-1b	GeneSeq Accession Y26176	WO9929728	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Immune disorders

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
MCP-1 receptor	GeneSeq Accession R79165	WO9519436	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138; Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Soluble MCP-1 Receptor polypeptides may be useful for inhibiting chemokine activities and viral infection.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
MCP-3	GeneSeq Accession R73915	WO9509232	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Immune disorders

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
MCP-4 receptor	GeneSeq Accession W56689	WO9809171	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Soluble MCP-4 Receptor polypeptides may be useful for inhibiting chemokine activities and viral infection.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
RANTES receptor	GeneSeq Accession W26588	US5652133	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Soluble RANTES Receptor polypeptides may be useful for inhibiting chemokine activities and viral infection.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
CCR5 variant	GeneSeq Accession W88238	WO9854317	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Soluble CCR5 polypeptides may be useful for inhibiting chemokine activities and viral infection.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
CCR7	GeneSeq Accession B50859	US6153441	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Soluble CCR7 polypeptides may be useful for inhibiting chemokine activities and viral infection.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
CXC3	GeneSeq Accession W23345	WO9727299	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Immune disorders

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Eotaxin	GeneSeq Accession W10099	WO9700960	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Immune disorders
Neurotactin	GeneSeq Accessions Y77537, W34307, Y53259, and Y77539	US6013257 WO9742224	Neurotactin may play a role in chemotactic leukocyte migration and brain inflammation processes.	Chemotactic leukocyte migration assays are known in the art, for example: J. Immunol. Methods 33, ((1980)); Nature 1997 Jun 5;387(6633):611-7.	Immune disorders

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human CKbeta-9	GeneSeq Accession B50860	US6153441	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Immune disorders
Lymphotactin	GeneSeq Accession B50052	WO0073320	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Immune disorders

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
MIP-3 alpha	GeneSeq Accession W44398	WO9801557	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Immune disorders
MIP-3 beta	GeneSeq Accession W44399	WO9801557	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Immune disorders

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
MIP-Gamma	GeneSeq Accession R70798	WO9504158	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Immune disorders
Stem Cell Inhibitory Factor	GeneSeq Accession R11553	WO9104274	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Hematopoietic growth factors
thrombopoietin	GeneSeq Accession R79905	WO9521920	Thrombopoietin is involved in the regulation of the growth and differentiation of megakaryocytes and precursors thereof.	Thrombopoietin (TPO) can be assayed to determine regulation of growth and differentiation of megakaryocytes. Mol Cell Biol 2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and within.	Hematopoietic growth factors

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
c-kit ligand; SCF; Mast cell growth factor; MGF; Fibrosarcoma-derived stem cell factor	GeneSeq Accession Y53284, R83978 and R83977	EP992579 and EP676470	c-kit ligand is thought to stimulate the proliferation of mast cells, and is able to augment the proliferation of both myeloid and lymphoid hematopoietic progenitors in bone marrow culture. C-kit ligand is also thought to act synergistically with other cytokines.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Hematopoietic growth factors
Platelet derived growth factor	GeneSeq Accession B48653	WO0066736	Vascular Endothelial Growth Factor	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
Melanoma inhibiting protein	GeneSeq Accession R69811	WO9503328	Melanoma inhibiting protein has melanoma-inhibiting activity and can be used to treat cancer (melanoma, glioblastoma, neuroblastoma, small cell lung cancer, neuroectodermal tumours) or as an immunosuppressant (it inhibits IL-2 or phytohaemagglutinin induced proliferation of peripheral blood lymphocytes).	Tumor suppressor activity of melanoma inhibiting protein can be determined using assays known in the art: Matznk et al., Nature 1992 Nov 26;360(6402):313-9.	Cancer; melanoma
Glioma-derived growth factor	GeneSeq Accession R08120	EP399816	Vascular Endothelial Growth Factor	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Platelet derived growth factor precursor A	GeneSeq Accession R84759	EP682110	Vascular Endothelial Growth Factor	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
Platelet derived growth factor precursor B	GeneSeq Accession R84760	EP682110	Vascular Endothelial Growth Factor	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
Platelet derived growth factor Bv-sis	GeneSeq Accessions P80595 and P80596	EP282317	Vascular Endothelial Growth Factor	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
Placental Growth Factor	GeneSeq Accessions R23059 and R23060	WO9206194	Vascular Endothelial Growth Factor	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
Placental Growth Factor-2	GeneSeq Accession Y08289	DE19748734	Vascular Endothelial Growth Factor	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Thrombopoietin derivative1	GeneSeq Accession Y77244	WO00000612	Thrombopoietin is involved in the regulation of the growth and differentiation of megakaryocytes and precursors thereof.	Thrombopoietin (TPO) can be assayed to determine regulation of growth and differentiation of megakaryocytes. Mol Cell Biol 2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and within.	Thrombocytopenia, cancer
Thrombopoietin derivative2	GeneSeq Accession Y77255	WO00000612	Thrombopoietin is involved in the regulation of the growth and differentiation of megakaryocytes and precursors thereof.	Thrombopoietin (TPO) can be assayed to determine regulation of growth and differentiation of megakaryocytes. Mol Cell Biol 2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and within.	Thrombocytopenia, cancer
Thrombopoietin derivative3	GeneSeq Accession Y77262	WO00000612	Thrombopoietin is involved in the regulation of the growth and differentiation of megakaryocytes and precursors thereof.	Thrombopoietin (TPO) can be assayed to determine regulation of growth and differentiation of megakaryocytes. Mol Cell Biol 2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and within.	Thrombocytopenia, cancer
Thrombopoietin derivative4	GeneSeq Accession Y77267	WO00000612	Thrombopoietin is involved in the regulation of the growth and differentiation of megakaryocytes and precursors thereof.	Thrombopoietin (TPO) can be assayed to determine regulation of growth and differentiation of megakaryocytes. Mol Cell Biol 2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and within.	Thrombocytopenia, cancer
Thrombopoietin derivative5	GeneSeq Accession Y77246	WO00000612	Thrombopoietin is involved in the regulation of the growth and differentiation of megakaryocytes and precursors thereof.	Thrombopoietin (TPO) can be assayed to determine regulation of growth and differentiation of megakaryocytes. Mol Cell Biol 2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and within.	Thrombocytopenia, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Thrombopoietin derivative6	GeneSeq Accession Y77253	WO0000612	Thrombopoietin is involved in the regulation of the growth and differentiation of megakaryocytes and precursors thereof.	Thrombopoietin (TPO) can be assayed to determine regulation of growth and differentiation of megakaryocytes. Mol Cell Biol 2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and within.	Thrombocytopenia, cancer
Thrombopoietin derivative7	GeneSeq Accession Y77256	WO0000612	Thrombopoietin is involved in the regulation of the growth and differentiation of megakaryocytes and precursors thereof.	Thrombopoietin (TPO) can be assayed to determine regulation of growth and differentiation of megakaryocytes. Mol Cell Biol 2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and within.	Thrombocytopenia, cancer
Fractalkine	GeneSeq Accession Y53255	US6043086	Fractalkine is believed to play a role in chemotactic leukocyte migration and neurological disorders.	Fractalkine activity can be determined using Chemotactic leukocyte migration assays known in the art, for example: J. Immunol. Methods 33, ((1980)); Nature 1997 Jun 5;387(6633):611-7.	Immune disorders

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
CXC3	GeneSeq Accession W23345	WO9727299	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138; Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Immune disorders

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
CCR7	GeneSeq Accession B50859	US6153441	Chemokines are a family of related small, secreted proteins involved in biological processes ranging from hematopoiesis, angiogenesis, and leukocyte trafficking. Members of this family are involved in a similarly diverse range of pathologies including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ~17 receptors thus far identified.	Chemokine activities can be determined using assays known in the art: Methods in Molecular Biology, 2000, vol. 138: Chemokine Protocols. Edited by: A.E.I. Proudfoot, T.N.C. Wells, and C.A. Power. © Humana Press Inc., Totowa, NJ	Soluble CCR7 polypeptides may be useful for inhibiting chemokine activities and viral infection.
Nerve Growth Factor-beta	GeneSeq Accession R11474	EP414151	Nerve Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266)	Neurological disorders, cancer
Nerve Growth Factor-beta2	GeneSeq Accession W69725	EP859056	Nerve Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266)	Neurological disorders, cancer
Neurotrophin-3	GeneSeq Accession W48839	WO9821234	Neurotrophins regulate neuronal cell survival and synaptic plasticity.	Trk tyrosine kinase activation assays known in the art can be used to assay for neurotrophin activity, for example, Proc Natl Acad Sci U S A 2001 Mar 13;98(6):3555-3560.	Neurological disorders, cancer
Neurotrophin-4	GeneSeq Accession R47100	WO9325684	Neurotrophins regulate neuronal cell survival and synaptic plasticity.	Trk tyrosine kinase activation assays known in the art can be used to assay for neurotrophin activity, for example, Proc Natl Acad Sci U S A 2001 Mar 13;98(6):3555-3560.	Neurological disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Neurotrophin-4a	GeneSeq Accession R47101	WO9325684	Neurotrophins regulate neuronal cell survival and synaptic plasticity.	Trk tyrosine kinase activation assays known in the art can be used to assay for neurotrophin activity, for example, Proc Natl Acad Sci U S A 2001 Mar 13;98(6):3555-3560. 13;98(6):3555-3560	Neurological disorders, cancer
Neurotrophin-4b	GeneSeq Accession R47102	WO9325684	Neurotrophins regulate neuronal cell survival and synaptic plasticity. tyrosine kinases.	Trk tyrosine kinase activation assays known in the art can be used to assay for neurotrophin activity, for example, Proc Natl Acad Sci U S A 2001 Mar 13;98(6):3555-3560.	Neurological disorders, cancer
Neurotrophin-4c	GeneSeq Accession R47103	WO9325684	Neurotrophins regulate neuronal cell survival and synaptic plasticity.	Trk tyrosine kinase activation assays known in the art can be used to assay for neurotrophin activity, for example, Proc Natl Acad Sci U S A 2001 Mar 13;98(6):3555-3560.	Neurological disorders, cancer
Neurotrophin-4d	GeneSeq Accession R47104	WO9325684	Neurotrophins regulate neuronal cell survival and synaptic plasticity.	Trk tyrosine kinase activation assays known in the art can be used to assay for neurotrophin activity, for example, Proc Natl Acad Sci U S A 2001 Mar 13;98(6):3555-3560.	Neurological disorders, cancer
Platelet-Derived Growth Factor A chain	GeneSeq Accession R38918	US5219739	Vascular Endothelial Growth Factor	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Hematopoietic and immune disorders. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Platelet-Derived Growth Factor B chain	GeneSeq Accession R38919	US5219739	Vascular Endothelial Growth Factor	VEGF activity can be determined using assays known in the art, such as those disclosed in International Publication No. WO0045835, for example.	Promotion of growth and proliferation of cells, such as vascular endothelial cells. Hematopoietic and immune disorders. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer
Stromal Derived Factor-1 alpha	GeneSeq Accession Y39995	WO9948528	Stromal Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266)	Hematopoietic, immune disorders, cancer
Stromal Derived Factor-1 beta	GeneSeq Accession R75420	CA2117953	Stromal Growth Factor	Proliferation assay using NR6R-3T3 cells (Rizzino 1988 Cancer Res. 48: 4266)	Hematopoietic, immune disorders, cancer
Tarc	GeneSeq Accession W14917	WO9711969	Chemotactic for T lymphocytes. May play a role in T-cell development. Thought to bind CCR8 and CCR4	Chemotactic leukocyte migration assays are known in the art, for example: J. Immunol. Methods 33, ((1980))	Antiinflammatory. Immune disorders, cancer
Prolactin	GeneSeq Accession R78691	WO9521625	Prolactin is involved in immune cell proliferation and apoptosis.	Immune cell proliferation and suppression of apoptosis by prolactin can be assayed by methods well-known in the art, for example, Buckley, AR and Buckley DJ, Ann N Y Acad Sci 2000; 917:522-33, and within.	Reproductive system disorders, cancer.
Prolactin2	GeneSeq Accession Y31764	US5955346	Prolactin is involved in immune cell proliferation and apoptosis.	Immune cell proliferation and suppression of apoptosis by prolactin can be assayed by methods well-known in the art, for example, Buckley, AR and Buckley DJ, Ann N Y Acad Sci 2000; 917:522-33, and within.	Reproductive system disorders, cancer.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Follicle stimulating hormone Alpha subunit	GeneSeq Accession Y54160	EP974359	FSH stimulates secretion of interleukin-1 by cells isolated from women in the follicular phase	FSH activities can be determined using assays known in the art: J Gend Specif Med 1999 Nov-Dec;2(6):30-4 ; Mol Cell Endocrinol. 1997 Nov 15;134(2):109-18.	Reproductive system disorders, cancer
Follicle stimulating hormone Beta subunit	GeneSeq Accession Y54161	EP974359	FSH stimulates secretion of interleukin-1 by cells isolated from women in the follicular phase	FSH activities can be determined using assays known in the art: J Gend Specif Med 1999 Nov-Dec;2(6):30-4 ; Mol Cell Endocrinol. 1997 Nov 15;134(2):109-18.	Reproductive system disorders, cancer
Substance P (tachykinin)	GeneSeq Accession B23027	WO0054053	Substance P is associated with immunoregulation.	Immunoregulation and bone marrow cell proliferation by substance P can be assayed by methods well-known in the art, for example, Lai et al. Proc Natl Acad Sci USA 2001 Mar 27; 98(7):3970-5; Jallat-Daloz et al. Allergy Asthma Proc 2001 Jan-Feb; 22(1):17-23; Kahler et al. Exp Lung Res 2001 Jan-Feb; 27(1):25-46; and Adamus MA and Dabrowski ZJ. J Cell Biochem 2001; 81(3):499-506.	diabetes mellitus, hypertension, cancer
Oxytocin (Neurophysin I)	GeneSeq Accessions B24085 and B24086	WO0053755	Oxytocin is involved in the induction of prostaglandin (E2) release, as well as an increased amount of calcium release by smooth muscle cells.	Oxytocin and prostaglandin E(2) release and Oxytocin (Ca2+) increase can be assayed by methods well-known in the art, for example, Pavan et al., AM J Obstet Gynecol 2000 Jul; 183(1):76-82 and Holda et al., Cell Calcium 1996 Jul;20(1):43-51.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Vasopressin (Neurophysin II)	GeneSeq Accessions B24085 and B24086	WO0053755	Vasopressin is believed to have a direct antidiuretic action on the kidney, and it is thought to cause vasoconstriction of the peripheral vessels.	Vasopressin activity can be determined using assays known in the art, for example, Endocr Regul 1996 Mar;30(1):13-17.	inflammatory disorders, immunologic disorders, cancer
IL-1	GeneSeq Accession P60326	EP165654	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	inflammatory disorders, immunologic disorders, cancer
IL-1 mature	GeneSeq Accession R14855	EP456332	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
IL-1 beta	GeneSeq Accession Y08322	WO9922763	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	inflammatory disorders, immunologic disorders, cancer
IL-3 variants	GeneSeq Accessions P80382, P80383, P80384, and P80381	WO8806161	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Kitamura et al (1989) J Cell Physiol. 140 323-334.	inflammatory disorders, immunologic disorders, cancer
IL-4	GeneSeq Accession P70615	WO8702990	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Siegel & Mostowski (1990) J Immunol Methods 132:287-295.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
IL-4 muteins	GeneSeq Accessions W52151, W52152, W52153, W52154, W52155, W52156, W52157, W52158, W52159, W52160, W52161, W52162, W52163, W52164, and W52165	WO9747744	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Siegel & Mostowski (1990) <i>J Immunol Methods</i> 132,287-295.	inflammatory disorders, immunologic disorders, cancer
IL-1 alpha	GeneSeq Accession P90108	EP324447	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) <i>Cytokine</i> 1, 14-20.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
IL-3 variants	GeneSeq Accessions R38561, R38562, R38563, R38564, R38565, R38566, R38567, R38568, R38569, R38570, R38571, and R38572	WO9307171	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Kitamura et al (1989) J Cell Physiol. 140 323-334.	inflammatory disorders, immunologic disorders, cancer
IL-6	GeneSeq Accessions R45717 and R45718	WO9402512	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Aarden et al (1987) Eur. J. Immunol 17, 1411-16.	inflammatory disorders, immunologic disorders, cancer
IL-13	GeneSeq Accession R48624	WO9404680	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Bouteiller et al (1995) J. Immunol. Methods 181,29.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
IL-4 mutein Y124X	GeneSeq Accession R47182	DE4137333	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Siegel & Mostowski (1990) J Immunol Methods 132,287-295.	inflammatory disorders, immunologic disorders, cancer
IL-4 mutein Y124X	GeneSeq Accession R47183	DE4137333	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Siegel & Mostowski (1990) J Immunol Methods 132,287-295.	inflammatory disorders, immunologic disorders, cancer
IL-4 mutein Y124G	GeneSeq Accession R47184	DE4137333	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Siegel & Mostowski (1990) J Immunol Methods 132,287-295.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human Interleukin-10 (precursor)	GeneSeq Accession R41664	WO9317698	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Thompson-Snipes et al (1991) J. Exp. Med. 173, 507-510.	inflammatory disorders, immunologic disorders, cancer
Human Interleukin 10	GeneSeq Accession R42642	WO9318783-A	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Thompson-Snipes et al (1991) J. Exp. Med. 173, 507-510.	inflammatory disorders, immunologic disorders, cancer
Human interleukin-1 beta precursor.	GeneSeq Accession R42447	EP569042	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Interleukin-1alpha	GeneSeq Accession R45364	EP578278	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	inflammatory disorders, immunologic disorders, cancer
MIRAP	GeneSeq Accession R14400	WO9117184	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	inflammatory disorders, immunologic disorders, cancer
Human interleukin-3	GeneSeq Accession R22813	JP04063595	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Kitamura et al (1989) J Cell Physiol. 140 323-334.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human interleukin-3 variant	GeneSeq Accession R22814	JP04063595	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Kitamura et al (1989) J Cell Physiol. 140 323-334.	inflammatory disorders, immunologic disorders, cancer
IL-1i fragments	GeneSeq Accessions R35484 and R35485	EP541920	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	inflammatory disorders, immunologic disorders, cancer
IL-1 inhibitor (IL-1i).	GeneSeq Accessions R35486 and R35484	EP541920	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
ICE 22 kD subunit.	GeneSeq Accession R33780	EP533350	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	inflammatory disorders, immunologic disorders, cancer
ICE 20 kD subunit.	GeneSeq Accession R33781	EP533350	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	inflammatory disorders, immunologic disorders, cancer
ICE 10 kD subunit.	GeneSeq Accession R33782	EP533350	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human Interleukin-10 (precursor)	GeneSeq Accession R41664	WO9317698	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Thompson-Snipes et al (1991) J. Exp. Med. 173, 507-510.	inflammatory disorders, immunologic disorders, cancer
Human Interleukin 10.	GeneSeq Accession R42642	WO9318783	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Thompson-Snipes et al (1991) J. Exp. Med. 173, 507-510.	inflammatory disorders, immunologic disorders, cancer
Human interleukin-1 beta precursor	GeneSeq Accession R42447	EP569042-	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Kitamura et al (1989) J Cell Physiol. 140 323-334.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human interleukin-6	GeneSeq Accession R49041	WO9403492	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Aarden et al (1987) Eur. J. Immunol 17, 1411-16.	inflammatory disorders, immunologic disorders, cancer
Mutant Interleukin 6 S176R	GeneSeq Accession R54990	WO9411402-	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Aarden et al (1987) Eur. J. Immunol 17, 1411-16.	inflammatory disorders, immunologic disorders, cancer
Interleukin 6	GeneSeq Accession R55256	JP06145063	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Aarden et al (1987) Eur. J. Immunol 17, 1411-16.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Interleukin 8 (IL-8) receptor	GeneSeq Accession R53932	JP06100595	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Holmes et al (1991) Science 253, 1278-80.	Soluble IL-8 receptor polypeptides may be useful for inhibiting interleukin activities.
Human interleukin-7.	GeneSeq Accession R59919	US5328988	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Park et al (1990) J. Exp. Med. 171, 1073-79.	inflammatory disorders, immunologic disorders, cancer
IL-3 containing fusion protein.	GeneSeq Accessions R79342 and R79344	WO9521254	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Kitamura et al (1989) J Cell Physiol. 140 323-334.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
IL-3 mutant proteins	GeneSeq Accessions R79254, R79255, R79256, R79257, R79258, R79259, R79260, R79261, R79262, R79263, R79264, R79265, R79266, R79267, R79268, R79269, R79270, R79271, R79272, R79273, R79274, R79275, R79276, R79277, R79278, R79279, R79280, R79281, R79282, R79283, R79284, and R79285	WO9521254	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Kitamura et al (1989) <i>J Cell Physiol.</i> 140 323-334.	inflammatory disorders, immunologic disorders, cancer
IL-15	GeneSeq Accession R66927	ZA9402636	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Giri et al (1994) <i>EMBO J.</i> 13 2822-2830.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
IL-12 p40 subunit.	GeneSeq Accession R63018	AU9466072	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Hori et al (1987), <i>Blood</i> 70, 1069-1078.	inflammatory disorders, immunologic disorders, cancer
AGF	GeneSeq Accession R64240	WO9429344	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	inflammatory disorders, immunologic disorders, cancer
Human interleukin-12 40 kD subunit	GeneSeq Accession R79187	WO9519786	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Hori et al (1987), <i>Blood</i> 70, 1069-1078.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human interleukin-15 receptor from clone P1	GeneSeq Accession R90843	WO9530695	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and 'Giri et al (1994) EMBO J. 13 2822-2830.	Soluble IL-15 receptor polypeptides may be useful for inhibiting interleukin activities.
Human interleukin-7	GeneSeq Accession R92796	WO9604306	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Park et al (1990) J. Exp. Med. 171, 1073-79.	inflammatory disorders, immunologic disorders, cancer
interleukin-9	GeneSeq Accession R92797	WO9604306	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yang et al (1989) Blood 74, 1880-84.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
interleukin-3	GeneSeq Accession R92801	WO9604306	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Kitamura et al (1989) J Cell Physiol. 140 323-334.	inflammatory disorders, immunologic disorders, cancer
Human interleukin-5	GeneSeq Accession R92802	WO9604306	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Kitamura et al (1989) J Cell Physiol. 140, 323-334.	inflammatory disorders, immunologic disorders, cancer
Recombinant interleukin-16	GeneSeq Accession W33373	DE19617202	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Lim et al (1996) J. Immunol. 156, 2566-70.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human IL-16 protein	GeneSeq Accession W33234	DE19617202	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Lim et al (1996) J. Immunol. 156, 2566-70.	inflammatory disorders, immunologic disorders, cancer
Thr117 human interleukin 9	GeneSeq Accession W27521	WO9708321	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	inflammatory disorders, immunologic disorders, cancer
Met117 human interleukin 9	GeneSeq Accession W27522	WO9708321	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yang et al (1989) Blood 74, 1880-84.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human intracellular IL-1 receptor antagonist.	GeneSeq Accession W80777	US5817306	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	inflammatory disorders, immunologic disorders, cancer
Human interleukin-18 protein (IL-18)	GeneSeq Accession W77158	EP864585	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Ushio et al (1996) J. Immunol. 156, 4274-79.	inflammatory disorders, immunologic disorders, cancer
Human interleukin 18	GeneSeq Accession W77077	EP861663	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Ushio et al (1996) J. Immunol. 156, 4274-79.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human interleukin 18 derivatives	GeneSeq Accessions W77083, W77084, W77085, W77086, W77087, W77088, and W77089	EP861663	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Ushio et al (1996) J. Immunol. 156, 4274-79.	inflammatory disorders, immunologic disorders, cancer
Interleukin-9 (IL-9) mature protein (Thr117 version).	GeneSeq Accession W68158	WO9827997	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yang et al (1989) Blood 74, 1880-84.	inflammatory disorders, immunologic disorders, cancer
IL-9 mature protein variant (Met117 version).	GeneSeq Accession W68157	WO9827997	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yang et al (1989) Blood 74, 1880-84.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human IL-9 receptor protein variant #3.	GeneSeq Accession W64058	WO9824904	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yang et al (1989) Blood 74, 1880-84.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yang et al (1989) Blood 74, 1880-84.
Human IL-9 receptor protein variant fragment	GeneSeq Accession W64060	WO9824904	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yang et al (1989) Blood 74, 1880-84.	Soluble IL-9 receptor polypeptides may be useful for inhibiting interleukin activities.
Human IL-9 receptor protein variant fragment#3.	GeneSeq Accession W64061	WO9824904	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yang et al (1989) Blood 74, 1880-84.	Soluble IL-9 receptor polypeptides may be useful for inhibiting interleukin activities.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human Interleukin-12 p40 protein	GeneSeq Accession W51311	WO9817689	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Hori et al (1987), <i>Blood</i> 70, 1069-1078.	inflammatory disorders, immunologic disorders, cancer
Human Interleukin-12 p35 protein	GeneSeq Accession W51312	WO9817689	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Hori et al (1987), <i>Blood</i> 70, 1069-1078.	inflammatory disorders, immunologic disorders, cancer
Human protein with IL-16 activity	GeneSeq Accession W63753	DE19649233-	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Lim et al (1996) <i>J. Immunol.</i> 156, 2566-70.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human protein with IL-16 activity	GeneSeq Accession W59425	DE19649233-	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Lim et al (1996) J. Immunol. 156, 2566-70.	inflammatory disorders, immunologic disorders, cancer
Human interleukin-15	GeneSeq Accession W53878	US5747024	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Giri et al (1994) EMBO J. 13 2822-2830.	inflammatory disorders, immunologic disorders, cancer
Human wild-type interleukin-4 (hIL-4) protein	GeneSeq Accession W52149	WO9747744	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Siegel & Mostowski (1990) J Immunol Methods 132,287-295.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
interleukin-4 muteins	GeneSeq Accessions W52150, W52151, W52153, W52154, W52155, W52156, W52157, W52158, W52159, W52160, W52161, W52162, W52163, W52164, W52165, W52166, and W52167	WO9747744	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Siegel & Mostowski (1990) <i>J Immunol Methods</i> 132:287-295.	inflammatory disorders, immunologic disorders, cancer
Human interleukin 1 delta	GeneSeq Accession Y28408	WO9935268	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) <i>Cytokine</i> 1, 14-20.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human interleukin-1 receptor antagonist beta	GeneSeq Accession Y24395	WO9935268	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	inflammatory disorders, immunologic disorders, cancer
Human EDIRF II protein sequence	GeneSeq Accession Y22199	WO9932632	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	inflammatory disorders, immunologic disorders, cancer
Human EDIRF I protein sequence	GeneSeq Accession Y22197	WO9932632	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human IL-1RD10 protein sequence	GeneSeq Accession Y14131	WO9919480	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	Soluble IL-1RD10 receptor polypeptides may be useful for inhibiting interleukin activities.
Human IL-1RD9	GeneSeq Accession Y14122	WO9919480	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	Soluble IL-1RD9 receptor polypeptides may be useful for inhibiting interleukin activities.
Human DNAX interleukin-40	GeneSeq Accession Y09196	WO9919491	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
(DIL-40) alternative sequence	GeneSeq Accession Y09197	WO9919491	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	inflammatory disorders, immunologic disorders, cancer
IL-11	GeneSeq Accession R50176	WO9405318	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Lu et al (1994) J Immunol. Methods 173, 19.	inflammatory disorders, immunologic disorders, cancer
Human adipogenesis inhibitory factor	GeneSeq Accession R43260	EP566410	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
IL-11	GeneSeq Accession W02202	JP08127539	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Lu et al (1994) J Immunol. Methods 173, 19.	inflammatory disorders, immunologic disorders, cancer
IL-14	GeneSeq Accession R55800	WO9416074	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Ambrus et al (1993) PNAS 90, 63330-34.	inflammatory disorders, immunologic disorders, cancer
IL-17 receptor	GeneSeq Accession B03807	US6072033	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yao et al (1995) J. Immunol. 155, 5483-86.	Soluble IL-17 receptor polypeptides may be useful for inhibiting interleukin activities.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
IL-17	GeneSeq Accession R76573	WO9518826	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yao et al (1995) J. Immunol. 155, 5483-86.	inflammatory disorders, immunologic disorders, cancer
CTLA-8	GeneSeq Accession W13651	WO9704097	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	inflammatory disorders, immunologic disorders, cancer
IL-19	GeneSeq Accession W37935	WO9808870	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Gallagher et al (2000) Genes Immun. 1, 442-50.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
IL-21 (TIF)	GeneSeq Accession Y92879	WO0024758	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Parrish-Novak et al (2000) Nature 408, 57-63.	inflammatory disorders, cancer immunologic disorders,
IL-8 receptor	GeneSeq Accession R33420	WO9306229	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Holmes et al (1991) Science 253, 1278-80.	Soluble IL-8 receptor polypeptides may be useful for inhibiting interleukin activities.
Human type II interleukin-1 receptor	GeneSeq Accession R85480	US5464937	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	Soluble type II interleukin-1 receptor polypeptides may be useful for inhibiting interleukin activities.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human interleukin-12 receptor	GeneSeq Accession R69632	EP638644	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Hori et al (1987), Blood 70, 1069-1078.	Soluble IL-12 receptor polypeptides may be useful for inhibiting interleukin activities.
Interleukin 8 receptor B	GeneSeq Accession R80758	US5440021	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Holmes et al (1991) Science 253, 1278-80.	Soluble IL-8 receptor B polypeptides may be useful for inhibiting interleukin activities.
Human IL-8 receptor protein hIL8RA	GeneSeq Accession B09989	JP08103276	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Holmes et al (1991) Science 253, 1278-80.	Soluble IL-8 receptor A polypeptides may be useful for inhibiting interleukin activities.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human IL-8 receptor protein hIL8RB	GeneSeq Accession B09990	JP08103276	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Holmes et al (1991) <i>Science</i> 253, 1278-80.	Soluble IL-8 receptor polypeptides may be useful for inhibiting interleukin activities.
Interleukin-2 receptor associated protein p43	GeneSeq Accession R97569	WO9621732-	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Gillis et al (1978) <i>J. Immunol.</i> 120, 2027.	Soluble IL-2 receptor polypeptides may be useful for inhibiting interleukin activities.
Human interleukin-17 receptor	GeneSeq Accession W04185	WO9629408	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yao et al (1995) <i>J. Immunol.</i> 155, 5483-86.	Soluble IL-17 receptor polypeptides may be useful for inhibiting interleukin activities.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human interleukin-11 receptor	GeneSeq Accession R99090	WO9619574	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Lu et al (1994) J Immunol. Methods 173, 19.	Soluble IL-11 receptor polypeptides may be useful for inhibiting interleukin activities.
Human interleukin-1 receptor accessory protein	GeneSeq Accession W01911	WO9623067	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	inflammatory disorders, immunologic disorders, cancer
AGF Protein	GeneSeq Accession R92749	US5488032	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	inflammatory disorders, immunologic disorders, cancer

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human interleukin-1 type-3 receptor	GeneSeq Accession R91064	WO9607739	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Orencole & Dinarello (1989) Cytokine 1, 14-20.	Soluble IL- type-3 receptor polypeptides may be useful for inhibiting interleukin activities.
Human interleukin-13 beta receptor	GeneSeq Accession W24972	WO9720926	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Boutelier et al (1995) J. Immunol. Methods 181,29.	Soluble IL-13 beta receptor polypeptides may be useful for inhibiting interleukin activities.
Human interleukin-13 alpha receptor	GeneSeq Accession W24973	WO9720926	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Boutelier et al (1995) J. Immunol. Methods 181,29.	Soluble IL-13 alpha receptor polypeptides may be useful for inhibiting interleukin activities.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human interleukin-4 receptor	GeneSeq Accession W13499	US5599905	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Siegel & Mostowski (1990) <i>J Immunol Methods</i> 132,287-295.	Soluble IL-4 receptor polypeptides may be useful for inhibiting interleukin activities.
Human interleukin-12 beta-2 receptor	GeneSeq Accession W12771	EP759466	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Hori et al (1987), <i>Blood</i> 70, 1069-1078.	Soluble IL-12 beta-2 receptor polypeptides may be useful for inhibiting interleukin activities.
Human interleukin-12 beta-1 receptor.	GeneSeq Accession W12772	EP759466	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Hori et al (1987), <i>Blood</i> 70, 1069-1078.	Soluble IL-12 beta-1 receptor polypeptides may be useful for inhibiting interleukin activities.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human IL-9 receptor protein	GeneSeq Accessions W64055, W64056, and W64057	WO9824904	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yang et al (1989) Blood 74, 1880-84.	Soluble IL-9 receptor polypeptides may be useful for inhibiting interleukin activities.
IL-10 receptor	GeneSeq Accession W41804	US5716804	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Thompson-Snipes et al (1991) J. Exp. Med. 173, 507-510.	Soluble IL-10 receptor polypeptides may be useful for inhibiting interleukin activities.
Human IL-6 receptor	GeneSeq Accession Y30938	JP11196867	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Aarden et al (1987) Eur. J. Immunol 17, 1411-16.	Soluble IL-6 receptor polypeptides may be useful for inhibiting interleukin activities.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
IL-17 receptor	GeneSeq Accession Y97181	US6096305	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yao et al (1995) J. Immunol. 155, 5483-86.	Soluble IL-17 receptor polypeptides may be useful for inhibiting interleukin activities.
IL-17 receptor	GeneSeq Accession Y97131	US6100235	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Yao et al (1995) J. Immunol. 155, 5483-86.	Soluble IL-17 receptor polypeptides may be useful for inhibiting interleukin activities.
human interleukin-3 receptor	GeneSeq Accession R25300	EP509826	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Kitamura et al (1989) J Cell Physiol. 140 323-334.	Soluble IL-3 receptor polypeptides may be useful for inhibiting interleukin activities.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Human GM-CSF receptor	GeneSeq Accession R10919	WO9102063	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	Soluble GM-CSF receptor polypeptides may be useful for inhibiting interleukin activities.
Human IL-5 receptor alpha chain	GeneSeq Accession R25064	EP492214	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Kitamura et al (1989) J Cell Physiol. 140, 323-334.	Soluble IL-5 receptor alpha polypeptides may be useful for inhibiting interleukin activities.
IL-5 receptor	GeneSeq Accession W82842	WO9847923	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Kitamura et al (1989) J Cell Physiol. 140, 323-334.	Soluble IL-5 receptor polypeptides may be useful for inhibiting interleukin activities.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
IL-6 receptor	GeneSeq Accession R37215	JP05091892	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Aarden et al (1987) Eur. J. Immunol 17, 1411-16.	Soluble IL-6 receptor polypeptides may be useful for inhibiting interleukin activities.
human B cell stimulating factor-2 receptor	GeneSeq Accession P90525	AU8928720	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225.	Soluble B cell stimulating factor-2 receptor polypeptides may be useful for inhibiting interleukin activities.
IL-7 receptor clone	GeneSeq Accession R08330	EP403114	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Park et al (1990) J. Exp. Med. 171, 1073-79.	Soluble IL-7 receptor polypeptides may be useful for inhibiting interleukin activities.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
EPO receptor; EPOR	GeneSeq Accession R06512	WO9008822	EPO Receptor is involved in the proliferation and differentiation of erythroblasts.	EPO Receptor activity can be determined using assays known in the art, such as, J Biol Chem 2001 Mar 23;276(12):8995-9002; JAK2 protein tyrosine kinase activity: Blood 1994 Sep 1;84(5):1501-7 and Mol Cell Biol. 1994 Oct;14(10):6506-14.	inflammatory disorders, immunologic disorders, cancer, erythroblast proliferation and differentiation
IL-15 receptor	GeneSeq Accession R90843	WO9530695	Interleukins are a group of multifunctional cytokines synthesized by lymphocytes, monocytes, and macrophages. Known functions include stimulating proliferation of immune cells (e.g., T helper cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.	Interleukin activity can be determined using assays known in the art: Matthews et al., in <i>Lymphokines and Interferons: A Practical Approach</i> , Clemens et al., eds, IRL Press, Washington, D.C. 1987, pp. 221-225; and Giri et al (1994) EMBO J. 13 2822-2830.	Soluble IL-15 receptor polypeptides may be useful for inhibiting interleukin activities.
CD137; 4-1BB Receptor Protein	GeneSeq Accession R70977	WO9507984	Activities associated with apoptosis, NF-kB activation, and co-stimulation of immune cells such as T and B cells.	Apoptosis activity, NF-kB activation, and B and T cell co-stimulation can be determined using assays known in the art: Moore et al., 1999, Science, 285(5425):260-3; Song HY et al., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J. Immunol. Methods.	Soluble 4-1BB receptor polypeptides may be useful for inhibiting apoptosis, NF-kB activation, and/or co-stimulation of immune cells such as B and T cells.

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Number	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
BCMA	GeneSeq Accession Y71979	WO0068378	Activities associated with apoptosis, NF-kB activation, and co-stimulation of immune cells such as T and B cells.	Apoptosis activity, NF-kB activation, and B and T cell co-stimulation can be determined using assays known in the art: Moore et al., 1999, Science, 285(5425):260-3; Song HY et al., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J. Immunol. Methods.	Soluble BCMA receptor polypeptides may be useful for inhibiting apoptosis, NF-kB activation, and/or co-stimulation of immune cells such as B and T cells.
CD27	GeneSeq Accession R20814	WO9201049	Activities associated with apoptosis, NF-kB activation, and co-stimulation of immune cells such as T and B cells.	Apoptosis activity, NF-kB activation, and B and T cell co-stimulation can be determined using assays known in the art: Moore et al., 1999, Science, 285(5425):260-3; Song HY et al., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J. Immunol. Methods.	Soluble CD27 polypeptides may be useful for inhibiting apoptosis, NF-kB activation, and/or co-stimulation of immune cells such as B and T cells.
CD30	GeneSeq Accession R35478	DE4200043	Activities associated with apoptosis, NF-kB activation, and co-stimulation of immune cells such as T and B cells.	Apoptosis activity, NF-kB activation, and B and T cell co-stimulation can be determined using assays known in the art: Moore et al., 1999, Science, 285(5425):260-3; Song HY et al., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J. Immunol. Methods.	Soluble CD30 polypeptides may be useful for inhibiting apoptosis, NF-kB activation, and/or co-stimulation of immune cells such as B and T cells.